Axoft, a Cambridge, Massachusetts-based neurotechnology company, has raised $55 million in an oversubscribed Series A financing round to accelerate the development and clinical expansion of its implantable brain-computer interface technology. The round was led by C.P. Group Innovation, with participation from Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. The latest investment brings Axoft’s total funding to more than $60 million and positions the company to advance global clinical trials, pursue U.S. regulatory approval, and scale manufacturing.
Advancing Implantable Brain-Computer Interfaces
Axoft is developing implantable brain-computer interfaces, or iBCIs, designed to capture high-resolution neural activity directly from the brain. The company says its technology has already demonstrated the ability to safely decode brain signals, with potential applications in prognosis and communication for patients with disorders of consciousness. These systems could help clinicians access neural information that traditional neurological exams and external imaging tools may not fully capture.
Neurological disorders remain a major global health challenge, affecting an estimated one in three people worldwide. By enabling more detailed access to brain signals, iBCIs could support AI-driven tools that identify disease biomarkers, guide personalized treatment strategies, and improve clinical decision-making. Axoft also sees high-quality neural data as a foundation for future AI models focused on brain health and biological intelligence.
A Softer Material Platform
A central part of Axoft’s approach is its proprietary Fleuron material, which is designed to improve the long-term performance of neural implants. Conventional brain implants are often made with rigid materials that can contribute to tissue scarring and movement, reducing signal quality over time. Axoft says Fleuron is significantly softer than polyimide, a material commonly used in existing iBCIs, and can support more stable neural recordings over longer periods.
According to the company, Fleuron enables broader access to brain regions, higher sensor density, and reduced signal attenuation compared with standard flexible probes. The material is also being positioned for uses beyond neural interfaces, including biohybrid devices, organ-on-a-chip systems, microfluidics, and other hardware-biology applications. This gives Axoft a dual opportunity: advancing its own medical devices while making the material platform available to researchers and industry partners.
Clinical and Research Progress
Since its seed financing in 2022, Axoft has reported meaningful progress in early clinical and research programs. The company has completed first-in-human clinical trials involving more than 11 patients worldwide and has supported research published in Nature in December 2023 and June 2025. Those studies demonstrated how Axoft’s proprietary materials can support scalable single-cell electrophysiology, an area relevant to both neuroscience research and future clinical applications.
Recent collaborations include work with Mass General Brigham on human cortical mapping, seizure onset mapping around tumors, and language recognition tasks. Axoft also completed a first-in-human study with The Panama Clinic, where its iBCIs were implanted in four patients undergoing brain tumor resection and used to record brain activity across cortical and subcortical regions. These developments suggest the company is moving from laboratory validation toward broader clinical testing in complex neurological settings.
Manufacturing and Global Expansion
The new funding will also support Axoft’s plans to build a good manufacturing practice cleanroom in Boston for mass production of its iBCIs and materials. The company has received grant support from the Massachusetts Manufacturing Innovation Initiative for this effort, which is expected to strengthen its ability to meet regulatory and commercial requirements. Axoft is also expanding its software engineering, microfabrication, and chemistry teams as it prepares for the next phase of development.
Beyond the United States, Axoft has opened a subsidiary in Grenoble, France, to access the region’s deep technology, medtech, and neuroscience ecosystem. The company has also launched Fleuron commercially through an exclusive licensing agreement with Stanford University and entered a joint development agreement with Kayaku Advanced Materials. These moves broaden Axoft’s reach across clinical research, materials science, and biomedical engineering markets.
Axoft’s $55 million Series A marks a significant step for a company seeking to redefine how brain activity is measured, interpreted, and applied in medicine. Its strategy combines implantable neural interfaces, advanced materials, AI-driven data analysis, and scalable manufacturing infrastructure. If its clinical programs continue to progress, Axoft could become an important player in the emerging market for next-generation brain-computer interfaces and neurological care.